Patents by Inventor Oskar SMRZKA
Oskar SMRZKA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12011484Abstract: A compound for the sequestration of undesirable antibodies (e.g. related to an autoimmune disease) in a patient. The compound includes an inert biopolymer scaffold and at least a first peptide n-mer of the general formula P(—S—P)(n?1) and a second peptide n-mer of the general formula P(—S—P)(n?1); wherein, independently for each occurrence, P is a peptide with a sequence length of 2-13 amino acids and S is a non-peptide spacer, wherein, independently for each of the peptide n-mers, n is an integer of at least 1, wherein each of the peptide n-mers is bound to the biopolymer scaffold. Also provided are pharmaceutical compositions including the compound, as well as a method of sequestering one or more antibodies present in an individual and a method of inhibiting an immune reaction to a treatment with an active agent.Type: GrantFiled: March 23, 2020Date of Patent: June 18, 2024Assignee: ABLEVIA BIOTECH GMBHInventors: Oskar Smrzka, Bettina Wanko
-
Patent number: 11986536Abstract: The present invention provides a compound for the sequestration of undesirable antibodies (e.g. related to an autoimmune disease) in a patient. The compound comprises an inert biopolymer scaffold and at least a first peptide n-mer of the general formula P(—S—P)(n-1) and a second peptide n-mer of the general formula P(—S—P)(n-1); wherein, independently for each occurrence, P is a peptide with a sequence length of 2-13 amino acids and S is a non-peptide spacer, wherein, independently for each of the peptide n-mers, n is an integer of at least 1, wherein each of the peptide n-mers is bound to the biopolymer scaffold. Also provided are pharmaceutical compositions comprising the compound, as well as a method of sequestering one or more antibodies present in an individual and a method of inhibiting an immune reaction to a treatment with an active agent.Type: GrantFiled: August 4, 2021Date of Patent: May 21, 2024Assignee: ABLEVIA BIOTECH GMBHInventors: Oskar Smrzka, Bettina Wanko
-
Publication number: 20230381334Abstract: A compound for the sequestration of undesirable antibodies (e.g. related to an autoimmune disease) in a patient includes an inert biopolymer scaffold, which is an anti-CD163 antibody or CD163-binding fragment thereof, and at least a first peptide n-mer of the general formula P(-S-P)(n-1) and a second peptide n-mer of the general formula P(-S-P)(n-1); wherein, independently for each occurrence, P is a peptide with a sequence length of 2-13 amino acids and S is a non-peptide spacer, wherein, independently for each of the peptide n-mers, n is an integer of at least 1, wherein each of the peptide n-mers is bound to the biopolymer scaffold. Also provided are pharmaceutical compositions including the compound, as well as a method of sequestering one or more antibodies present in an individual and a method of inhibiting an immune reaction to a treatment with an active agent.Type: ApplicationFiled: September 23, 2021Publication date: November 30, 2023Inventors: Oskar SMRZKA, Bettina WANKO
-
Publication number: 20230381328Abstract: A compound for the sequestration of anti human muscle nicotinic acetylcholine receptor (AChR) autoantibodies, which are involved in the pathogenesis of MG is provided. The compound includes an inert biopolymer scaffold and at least two peptides with a sequence length of 6-13 amino acids, wherein each of the peptides independently includes an amino-acid sequence including an AChR main immunogenic region (MIR) epitope or mimotope. Also provided are pharmaceutical compositions including the compound, as well as a method of sequestering one or more antibodies present in an individual.Type: ApplicationFiled: September 23, 2021Publication date: November 30, 2023Inventors: Oskar SMRZKA, Bettina WANKO
-
Publication number: 20230365655Abstract: A compound for the sequestration of undesirable antibodies associated with hemophilia A, in particular when treated by factor VIII replacement therapy. The compound includes a biopolymer scaffold and at least two peptides derived from factor VIII with a sequence length of 6-13 amino acid, wherein each of the peptides independently includes a 6-amino-acid fragment of the amino-acid sequence of factor VIII, optionally wherein at most three, preferably at most two, more preferably at most one amino acid is independently substituted by any other amino acid. Also provided are pharmaceutical compositions including the compound, as well as methods for treating hemophilia A.Type: ApplicationFiled: September 23, 2021Publication date: November 16, 2023Inventors: Oskar SMRZKA, Bettina WANKO
-
Publication number: 20230355660Abstract: A compound for the sequestration of undesirable anti-polyethylene glycol (PEG) antibodies interfering with therapy by PEGylated active agents (such as PEGylated enzymes or antibodies) in a patient is provided. The compound includes an inert biopolymer scaffold and one or more PEG chains. Also provided are pharmaceutical compositions including the compound, as well as a method of sequestering one or more anti-PEG antibodies present in an individual and a method of inhibiting an immune reaction to a treatment with a PEGylated active agent.Type: ApplicationFiled: September 23, 2021Publication date: November 9, 2023Inventors: Oskar SMRZKA, Bettina WANKO
-
Publication number: 20230355747Abstract: A compound for the sequestration of undesirable neutralizing antibodies against viral vectors in a patient. The compound includes an inert biopolymer scaffold and at least a first peptide n-mer of the general formula P ( - S - P ) (n-1) and a second peptide n-mer of the general formula P ( - S - P ) (n-1); wherein, P is a peptide with a sequence length of 2-13 amino acids and S is a non-peptide spacer, independently for each of the peptide n-mers, n is an integer of at least 1, each of the peptide n-mers is bound to the biopolymer scaffold. Independently for each occurrence, P has an amino-acid sequence including a sequence fragment with a length of at least six amino acids of a capsid protein sequence of a viral vector. Compositions including the compound and sequestering and inhibiting methods are also provided.Type: ApplicationFiled: September 23, 2021Publication date: November 9, 2023Inventors: Oskar SMRZKA, Bettina WANKO
-
Publication number: 20230355784Abstract: A compound for the sequestration of undesirable antibodies associated with an autoantibody-mediated condition, such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), postural orthostatic tachycardia syndrome (POTS), Autoimmune Autonomic Ganglionopathy (AAG), Idiopathic Dilated Cardiomyopathy (IDC), Chronic Chagas heart disease (cChHD) and other neurological, neuromuscular and neuropsychiatric disorders, in particular, autoimmune channelopathies is provided. The compound includes a biopolymer scaffold and at least two peptides with a sequence length of 6-13 amino acid, wherein each of the peptides independently comprises a 6-amino-acid fragment of an amino-acid sequence of a human neuroreceptor, optionally wherein at most three amino acids are independently substituted by any other amino acid. Also provided are pharmaceutical compositions including the compound, as well as methods of ameliorating or treating the conditions mentioned above.Type: ApplicationFiled: September 23, 2021Publication date: November 9, 2023Inventors: Oskar SMRZKA, Bettina WANKO
-
Publication number: 20220073650Abstract: Disclosed is an apheresis device including a solid carrier capable of being contacted with the blood or plasma flow, characterised in that the solid carrier includes one or several HTT-binding molecule (s) capable of adsorbing HTT or fragments thereof in a specific manner from plasma or blood or other HTT containing body fluids such as CSF.Type: ApplicationFiled: November 5, 2021Publication date: March 10, 2022Applicant: AFFIRIS AGInventors: Oskar SMRZKA, Stefan BARTL, Michela PARTH
-
Publication number: 20220062435Abstract: A compound for the sequestration of undesirable antibodies (e.g. related to an autoimmune disease) in a patient. The compound includes an inert biopolymer scaffold and at least a first peptide n-mer of the general formula P(—S—P)(n-1) and a second peptide n-mer of the general formula P(—S—P)(n-1); wherein, independently for each occurrence, P is a peptide with a sequence length of 2-13 amino acids and S is a non-peptide spacer, wherein, independently for each of the peptide n-mers, n is an integer of at least 1, wherein each of the peptide n-mers is bound to the biopolymer scaffold. Also provided are pharmaceutical compositions including the compound, as well as a method of sequestering one or more antibodies present in an individual and a method of inhibiting an immune reaction to a treatment with an active agent.Type: ApplicationFiled: March 23, 2020Publication date: March 3, 2022Inventors: Oskar SMRZKA, Bettina WANKO
-
Publication number: 20210369856Abstract: The present invention provides a compound for the sequestration of undesirable antibodies (e.g. related to an autoimmune disease) in a patient. The compound comprises an inert biopolymer scaffold and at least a first peptide n-mer of the general formula P(-S-P)(n-1) and a second peptide n-mer of the general formula P(-S-P)(n-1); wherein, independently for each occurrence, P is a peptide with a sequence length of 2-13 amino acids and S is a non-peptide spacer, wherein, independently for each of the peptide n-mers, n is an integer of at least 1, wherein each of the peptide n-mers is bound to the biopolymer scaffold. Also provided are pharmaceutical compositions comprising the compound, as well as a method of sequestering one or more antibodies present in an individual and a method of inhibiting an immune reaction to a treatment with an active agent.Type: ApplicationFiled: August 4, 2021Publication date: December 2, 2021Inventors: Oskar SMRZKA, Bettina WANKO
-
Publication number: 20210040236Abstract: Disclosed is an apheresis device including a solid carrier capable of being contacted with the blood or plasma flow, characterised in that the solid carrier includes one or several HTT-binding molecule(s) capable of adsorbing HTT or fragments thereof in a specific manner from plasma or blood or other HTT containing body fluids such as CSF.Type: ApplicationFiled: August 18, 2020Publication date: February 11, 2021Applicant: AFFIRIS AGInventors: Oskar SMRZKA, Stefan Bartl, Michela Parth
-
Patent number: 10406197Abstract: Disclosed are immunogenic peptides of the HTT protein and HTT specific antibodies for use in the prevention and/or treatment of Huntington's disease.Type: GrantFiled: July 10, 2015Date of Patent: September 10, 2019Assignee: AFFIRIS AGInventors: Oskar Smrzka, Stefan Bartl, Michela Parth
-
Publication number: 20190127438Abstract: Disclosed is an alpha chain of the human high-affinity IgE receptor (FceRIa), wherein the amino acid lysine at position 43 (K43) is exchanged with an amino acid selected from the group consisting of alanine, serine, tyrosine, isoleucine, leucine, asparagine, aspartic acid, methionine, phenylalanine, glutamic acid, threonine, glutamine, tryptophan, glycine, and valine, preferably alanine, glycine, serine or tyrosine, especially alanine.Type: ApplicationFiled: January 13, 2017Publication date: May 2, 2019Applicant: AFFIRIS AGInventors: Oskar SMRZKA, Marwa MOSTAGEER
-
Publication number: 20180327513Abstract: Disclosed is an apheresis device including a solid carrier capable of being contacted with the blood or plasma flow, characterised in that the solid carrier includes one or several HTT-binding molecule(s) capable of adsorbing HTT or fragments thereof in a specific manner from plasma or blood or other HTT containing body fluids such as CSF.Type: ApplicationFiled: July 2, 2018Publication date: November 15, 2018Applicant: AFFIRIS AGInventors: Oskar SMRZKA, Stefan Bartl, Michela Parth
-
Patent number: 10053518Abstract: Disclosed is an apheresis device comprising a solid carrier capable of being contacted with the blood or plasma flow, characterised in that the solid carrier includes one or several HTT-binding molecule(s) capable of adsorbing HTT or fragments thereof in a specific manner from plasma or blood or other HTT containing body fluids such as CSF.Type: GrantFiled: July 10, 2015Date of Patent: August 21, 2018Assignee: AFFIRIS AGInventors: Oskar Smrzka, Stefan Bartl, Michela Parth
-
Publication number: 20180186896Abstract: Disclosed is a vaccine for use in the prevention or treatment of an Immunoglobulin E (IgE-) related disease, comprising a peptide bound to a pharmaceutically acceptable carrier, wherein said peptide is selected from the group of QQQGLPRAAGG (SEQ ID No. 109; p9347), QQLGLPRAAGG (SEQ ID No. 110; p8599), QQQGLPRAAEG (SEQ ID No. I11; p8600), QQLGLPRAAEG (SEQ ID No. 112; p8601), QQQGLPRAAG (SEQ ID No. 113; p9338), QQLGLPRAAG (SEQ ID No. 114; p9041), QQQGLPRAAE (SEQ ID No. 115; p9042), QQLGLPRAAE (SEQ ID No. 116; p9043), HSGQQQGLPRAAGG (SEQ ID No. 117; p7575), HSGQQLGLPRAAGG (SEQ ID No. 118; p8596), HSGQQQGLPRAAEG (SEQ ID No. 119; p8597), HSGQQLGLPRAAEG (SEQ ID No. 120; p8598), QSQRAPDRVLCHSG (SEQ ID No. 121; p7580), GSAQSQRAPDRVL (SEQ ID No. 122; p7577), and WPGPPELDV (SEQ ID No. 125; p7585).Type: ApplicationFiled: July 7, 2016Publication date: July 5, 2018Applicant: AFFIRIS AGInventors: Oskar SMRZKA, Benjamin VIGL
-
Publication number: 20170304384Abstract: Disclosed are immunogenic peptides of the HTT protein and HTT specific antibodies for use in the prevention and/or treatment of Huntington's disease.Type: ApplicationFiled: July 10, 2015Publication date: October 26, 2017Applicant: AFFIRIS AGInventors: Oskar SMRZKA, Stefan BARTL
-
Publication number: 20170145117Abstract: Disclosed is an apheresis device comprising a solid carrier capable of being contacted with the blood or plasma flow, characterised in that the solid carrier includes one or several HTT-binding molecule (s) capable of adsorbing HTT or fragments thereof in a specific manner from plasma or blood or other HTT containing body fluids such as CSF.Type: ApplicationFiled: July 10, 2015Publication date: May 25, 2017Applicant: AFFIRIS AGInventors: Oskar SMRZKA, Stefan BARTL